RIMOXCLAMIN's Therapeutic Impact in a Larger Brazilian Hansen’s Disease Population

Clicks: 3
ID: 315937
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #94 of 208 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background RIMOXCLAMIN, a new antibiotic regimen for Hansen’s disease (HD), combines rifampicin, moxifloxacin, clarithromycin, and minocycline; the WHO-MDT combines rifampicin, dapsone, and clofazimine. To overcome limitations of WHO-MDT, we evaluated both regimens in a two-arm cohort of multibacillary patients. Methods Two-arm observational cohort included 162 newly diagnosed multibacillary cases (103 RIMOXCLAMIN; 59 WHO-MDT) evaluated between 2015-2025. Patients were assessed at least quarterly (baseline and months 3, 6, and 12) for neurological and cutaneous findings, adverse events, tactile sensitivity, and physical disability grade (PDG). Results Neurological symptoms were frequent regardless of lesion count (≤5 vs. >5; p>0.05). RIMOXCLAMIN demonstrated a greater reduction in nerve thickening than WHO-MDT (p< 0.0001) and increased PDG-0 from 18% to 82% (p< 0.0001), compared with 22% to 53% in the WHO-MDT group (p= 0.0006). RIMOXCLAMIN reduced PDG-2 by 67% at month 6 (p= 0.002) and 83% at discharge (p< 0.0001), whereas WHO-MDT showed no change at month 6 and a 50% reduction at discharge. At month three, neurological symptoms were greater in the RIMOXCLAMIN group than WHO-MDT, with no intragroup differences. WHO-MDT showed higher adverse events, including severe anemia (requiring dapsone discontinuation in 33.9% [20/59]. RIMOXCLAMIN adverse events were mild, requiring regimen adjustments in 19.4% (20/103) without additional medications. A general limitation is that the groups are not fully socioeconomically comparable. Conclusions RIMOXCLAMIN was safe and clinically advantageous as a first-line HD regimen, offering faster neurological recovery, disability reversal, and minimal adverse event. These findings support incorporating neurological parameters of skin sensory changes, as lesion count alone does not appear to be a reliable marker of the clinical and neurological severity.
Reference Key
openalex_W7163572831 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marco Andrey Cipriani Frade, Gustavo Sartori Albertino, Natália Aparecida de Paula, Fabiana Aparecida Correa Cinto, Fernanda Cruz Perecin, Andrezza Westin, Mariane de Moraes Monteiro, W M J Wilson Marques Junior, Helena Barbosa Lugão, Filipe Rocha Lima
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag332
URL
https://doi.org/10.1093/ofid/ofag332
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.